Connect your AI

OS Therapies OSTX Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Avalo TherapeuticsAVTX

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is OS Therapies's remainder of fiscal year 2024?: OS Therapies (OSTX) reported remainder of fiscal year 2024 of $372.73K in Q1 2026.